China’s Gastric Cancer Drug Market Will Grow to $469 Million in 2015

Surveyed Chinese Oncologists Use Branded Targeted Therapies Off Label for Late-Stage Gastric Cancer, According to a New Report from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that China’s gastric cancer drug market will grow from $250 million in 2010 to $469 million in 2015. According to the Emerging Markets report, Gastric Cancer in China, market growth will be driven by expansion of the diagnosed and drug treated population, greater access to chemotherapy agents used to treat gastric cancer, increased use of targeted therapies and improved patient spending power. The incidence of gastric cancer in China is one of the highest worldwide, surpassed only by Japan and Korea; gastric cancer incident cases will increase 1.6 percent annually in China between 2010 and 2015.

Although not approved by the Chinese government for gastric cancer treatment, branded targeted therapies including Bristol-Myers Squibb/Eli Lilly/ImClone Systems/Merck KGaA’s Erbitux, Roche’s Herceptin and Novartis’s Gleevac are currently prescribed off label by Chinese oncologists for gastric cancer treatment. Some targeted therapies, including Herceptin and two emerging agents, GlaxoSmithKline’s lapatinib and Novartis’s everolimus, will be launched in China by the end of the study forecast period, further contributing to growth in this market.

“In China, fourteen percent of gastric cancer patients are HER2-positive, so with Herceptin’s likely approval in China for treating HER2-positive gastric cancer patients, uptake of this agent will increase,” said Decision Resources Analyst Jing Wu, M.S., M.B.A. “Approvals in major markets will affect uptake as well. For instance, the anticipated 2013 launch of Erbitux for gastric cancer in the United States and Europe will also have a positive impact on the uptake of Erbitux among Chinese patients who can afford the treatment.”

The new report features extensive primary research with Chinese oncologists as well as a market outlook by drug and class through 2015.

About Emerging Markets Reports

Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.